Combined use of dipeptidyl peptidase 4 inhibitor and sweetener

摘要

The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity.

主权项

1. A method for reducing body weight or reducing body fat mass of a patient suffering from symptoms of obesity, comprising administering an effective amount of (a) at least one dipeptidyl peptidase 4 inhibitor and (b) at least one sweetener having a GLP-1 secretion-stimulating action to the patient suffering from symptoms of obesity; wherein the at least one sweetener having a GLP-1 secretion-stimulating action is
a non-saccharide sweetener chosen from acesulfame K, sucralose, aspartame, and stevia.